About the Journal

Precision Cancer Medicine

Aims and Scope

Precision Cancer Medicine (PCM, Precis Cancer Med, ISSN: 2617-2216) is an open access, peer-reviewed online journal dedicated to precise diagnosis and treatment of cancers and personalized care for patients. With an aim of better understanding and management of cancers, the journal focuses on precision cancer researches on different kinds of cancers and different aspects of cancer research, encompassing advanced basic researches, translational researches and up-to-date clinical practice in the field of precision medicine and engaging multidisciplinary teams of oncology, pathology, imaging, radiotherapy, chemotherapy, surgery, anesthesiology, nursing, etc. It is to improve the health care from all aspects of prevention, diagnosis, treatment and recovery management of cancer care for the patients. PCM welcomes submissions of Original Articles, Review Articles, Editorials, Editorial Commentaries, Case Reports, Clinical Guidelines, etc.

Precision Cancer Medicine is the official journal of Fudan University Shanghai Cancer Center.

Introduction of Fudan University Shanghai Cancer Center

Fudan University Shanghai Cancer Center (FUSCC, https://english.shca.org.cn/english), is engaged in clinical practice, medical education, oncological research and cancer prevention in China. Historically, it can be traced back to Sino-Belgian Radium Institute established on March 1, 1931, the earliest specialized hospital of oncology in China.

FUSCC topped the counterparts across the China in terms of medical operation efficiency. The year of 2017 witnessed 1,339,000 outpatient and emergency visits, including 160,000+ first visits; 37,284 surgeries and 76,381 hospitalizations. As to scientific research, they published 338 SCI papers in journals such as JCO, Nature, JNCI, etc.

FUSCC, while deeply committing to the basic mission to care for the patient, is dedicated to building national and international collaborative partnerships and cherishing its influential image.

Internationally, FUSCC signed the sister-institution agreement, respectively, with MD Anderson Cancer Center at Texas in USA; National University Cancer Institute Singapore; Institut Gustave Roussy in France; Cancer Research Institute of Kanazawa University, Japan; European Institute of Oncology, Italy; DUKE Cancer Institute, USA; Peter MacCallum Cancer Centre, Australia; and The Princess Margaret Cancer Centre, Canada for the purpose of promoting bilateral collaborations and exchanges in therapy, research, training and referral. So far, FUSCC has established eight sister-institution/hospital partnerships, advancing the construction of its own disciplines and improving its academic prestige in the world.


Precision Cancer Medicine is indexed and covered by

Information for Authors

PCM is a member of Committee on Publication Ethics (COPE) and it follows the Committee on Publication Ethics (COPE)'s guidelines and the ICMJE recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journal.

Manuscripts submitted must be the original work of the author(s) and must not be published previously or under consideration for publication elsewhere.

Submission Turnaround Time

  • In-house review: 1-3 weeks
  • External peer review: 1-3 months
  • Publication Ahead of Print: within 1 month after being accepted
  • Formal publication: within 1-3 months after being accepted. Original Articles are listed as priority.

Open Access Statement

This journal is a peer reviewed, open access journal. All content of the journal is published under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). All articles published open access will be immediately and permanently free for all to read, download, copy and distribute as defined by the applied license.

Free access and usage
Permitted third party reuse is defined by the CC BY-NC-ND 4.0 license. This license allows users to copy and distribute the article, provided:

  • this is not done for commercial purposes and further does not permit distribution of the Article if it is changed or edited in any way.
  • the user gives appropriate credit (with a link to the formal publication through the relevant DOI) and provides a link to the license but not in an any way implying that the licensor is endorsing the user or the use of the work.
  • no derivatives including remix, transform, or build upon the material was allowed for distribution.
The full details of the license are available at https://creativecommons.org/licenses/by-nc-nd/4.0/


For open access publishing, this journal uses an exclusive licensing agreement. Authors will transfer copyright to PCM, but will have the right to share their article in the same way permitted to third parties under the relevant user license, as well as certain scholarly usage rights.

For commercial usage or adaptation of PCM articles, please contact: permissions@amegroups.com

For reprint order, please contact: sales@amegroups.com

Support for Authors to Comply with Funding Body Mandates

We work with authors of research articles supported by funding bodies with open access mandates to ensure that authors can meet their funders’ requirements for public access to research results.

In addition, we offer further support for authors who are required to comply with funding body mandates, including but not limited to:

Editorial Office

Email: pcm@amegroups.com

Publisher Information

PCM is published by AME Publishing Company
Address: Flat/RM C 16F, Kings Wing Plaza 1, NO. 3 on Kwan Street, Shatin, NT, Hong Kong, China.

Updated on March 21, 2024